Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma

Peripheral T Cell Lymphoma Clinical Trial

Official title:

A Multicenter, Prospective and Single-arm Clinical Study on the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma (R/R PTCL) With Chidamide and Duvalisib

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06151106
• Other study ID #: XMDYYYXYK-02
• Status: Recruiting
• Phase: Phase 2
• Start date: November 22, 2023
• Est. completion date: December 25, 2025

Study information

• Verified date: December 2023
• Source: The First Affiliated Hospital of Xiamen University
• Contact: Bing Xu
• Phone: +8618750918842
• Email: xubingzhangjian[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To determine the efficacy and safety of Chidamide combined with Duvalisib in the treatment of refractory/relapsed peripheral T-cell lymphoma.

Description:

This is a Phase 2, open-label clinical trial study that aims to evaluate the efficacy (Overall Response Rate, Complete Response, Partial Response, Overall Survival, Progression Free Survival) and adverse effects of Chidamide combined with Duvalisib in the treatment of refractory/relapsed peripheral T-cell lymphoma.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 33
• Est. completion date: December 25, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Peripheral T-cell lymphoma (PTCL) or NK/T-cell lymphoma confirmed by histopathology/cytology according to the classification standard of the World Health Organization in 2008

2. Relapsed and refractory patients who have received at least first-line systemic treatment with anthracycline-containing drugs in the past. Recurrence is defined as relapse after CR or progression after PR, SD. The refractory disease was defined as previous systemic chemotherapy, PD in response evaluation for 2 cycles or SD in response evaluation for 4 cycles.

3. There must be at least one evaluable or measurable lesion meeting Lugano2014 standard:

lymph node lesion and the measurable lymph node length should be > 1.5cm;

4. Patients aged at 18-75 years old;

5. ECOG 0-2

6. Routine blood examination: absolute neutrophil count = 1.5× 10 9/L, platelet = 75x10 9/L, Hb = 80g/L.

7. Expected survival =3 months 8 No radiotherapy, chemotherapy, targeted therapy, or hematopoietic stem cell transplantation was received within 4 weeks before enrollment.

9. The patient or his/her legal representative must provide written informed consent before carrying out any special inspection or procedure of the study.

Exclusion Criteria:

1. Patients with central nervous system (CNS) or meningeal invasion

2. Any of the following laboratory abnormalities: absolute neutrophil count (ANC) < 1.5× 10*9/L, Hb< 80 g/L, PLT < 75×10 9 /L, organ dysfunction, are defined as follows: total bilirubin (TBiL) > 1.5 upper limit of normal value (ULN), or AST or ALT >2.5ULN, except the following situations. if patients with liver infiltrated by lymphoma cells, AST and ALT < 5ULN could be enrolled.

3. International normalized ratio (INR)>1.5ULN or partially activated prothrombin time (APTT) > 1.5 ULN

4. The active infection of human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) should be excluded except for the following patients: patients with HBV infection (HBsAg or HBcAg positive) but HBV DNA negative. These patients need continuous antiviral treatment and HBV DNA PCR detection every cycle. additionally, patients with HCV serology positive but HCV RNA negative can be enrolled.

5. In patients with CMV infection (IgM positive), CMV DNA was positive by PCR.

6. Meet any of the following criteria related to visceral function: all kinds of clinically significant abnormal rhythm or conduction need clinical pre-diagnosis Hereditary QT interval syndrome or QTcF>480 msec or taking drugs that may cause Qt interval delay or torsade de pointes. A variety of clinically significant cardiovascular diseases, including acute myocardial infarction, unstable angina, and coronary artery bypass grafting in the first 6 months of the group, with New York's cardiology (NYHA) classification of grade 3 or above. Left ventricular ejection fraction (LVEF )<40%, or uncontrolled blood pressure controlled by drugs (Systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mgHg).

7. Have a history of stroke or intracranial hemorrhage within 6 months before drug administration for the first time

8. Major surgery was performed within 4 weeks before drug administration for the first study

9. Any PI3K inhibitor has been used before and the disease has progressed during the treatment period (within 6 months after the last use)

10. Received systemic anti-tumor therapy or radiotherapy within 4 weeks before the first study drug administration

11. The last time you participated in clinical trials of other drugs before the administration of the first study drug was less than 2 weeks or the last time you used targeted drugs (such as antibody drugs) was less than 4 weeks

12. patients received the transplantation of somatic hematopoietic stem cells within 3 months before the first drug administration

13. Patients received allogeneic hematopoietic stem cell transplantation or having any active graft-versus-host disease within 6 months before first drug administration.

14. Take a strong inducer or inhibitor of cytochrome P4503A4 (CYP3A4) within 2 weeks before drug administration (3 weeks for Hypericum perforatum) for the first time.

15. Before the first enrollment, the toxic reaction of previous anti-tumor therapy has not recovered to =1 level (except alopecia).

16. Patients with uncontrolled systemic infection requiring intravenous antibiotic treatment

17. Currently suffering from other primary tumors that need active treatment according to the guidelines

18. Inability to take drugs orally, previous surgical history or serious gastrointestinal diseases such as dysphagia and active gastric ulcer may affect the absorption of drugs

19. Pregnant (serum pregnancy test results are positive) or lactating women

20. Any other diseases, abnormal metabolism, abnormal physical examination or abnormal laboratory examination with significant clinical significance, according to the researcher's judgment, it is reasonable to suspect that the patient has a certain disease or state that is not suitable for using these two drugs, or it will affect the interpretation of the research results or put the patient in a high-risk situation.

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, T-Cell
• Lymphoma, T-Cell, Peripheral
• Peripheral T Cell Lymphoma
• Refractory T-Cell Lymphoma
• Relapsed Peripheral T-Cell Lymphoma

Intervention

Drug:
• Chidamide combined with Duvillisib
Specified dose on specified days

Locations

Country	Name	City	State
China	The First Affiliated Hosptial of Xiamen University	Xiamen	Fujian

Sponsors (8)

Lead Sponsor	Collaborator
The First Affiliated Hospital of Xiamen University	Dongguan People's Hospital, Fujian Cancer Hospital, Huizhou Municipal Central Hospital, Shanxi Province Cancer Hospital, Sun Yat-sen University, The First Affiliated Hospital with Nanjing Medical University, Zhangzhou Affiliated Hospital of Fujian Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response Rate	Percentage of participants with best overall response of partial response (PR) and complete response (CR), using the Lugano criteria.	Up to 27 months
Primary	Complete Response Rate	Complete response (CR) is evaluated according to the Lugano criteria for lymphoma response.	Up to 27 months
Secondary	Partial Response Rate	Partial response (PR) is evaluated according to the Lugano criteria for lymphoma response.	Up to 27 months
Secondary	Progression Free Survival	Progression-free survival was defined as the time from the date of diagnosis until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria, or death from any cause, whichever occurred first.	Up to 27 months
Secondary	Overall Survival	OS will be measured from the date of registration to the date of the event (i.e., death) or the date of last follow-up to evaluate that event. Patients who are event-free at their last follow-up evaluation will be censored at that time point.	Up to 27 months